

Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

## Class: 4A\_NSCLC

### Annotations (1)

- `rdfs:comment` "Cancer that is limited in the lungs and has only spread to one other site (such as the brain) is not common, but it can sometimes be treated (and even potentially cured) with surgery and/or radiation therapy to treat the area of cancer spread, followed by treatment of the cancer in the lung. For example, a single tumor in the brain may be treated with surgery or stereotactic radiation, or surgery followed by radiation to the whole brain. Treatment for the lung tumor is then based on its T and N stages, and may include surgery, chemo, radiation, or some of these in combination."

### Superclasses (1)

- `Stage_4_NSCLC`

### Disjoints (689)

'\Abraxane\_(Paclitaxel\_Albumin-stabilized\_Nanoparticle\_Formulation)\_\'', '\Afinitor\_(Everolimus)\_\'', '\Afinitor\_Disperz\_(Everolimus)\_\'', '\Alecensa\_(Alectinib)\_\'', '\Alimta\_(Pemetrexed\_Disodium)\_\'', '\Alunbrig\_(Brigatinib)\_\'', '\Alymsys\_(Bevacizumab)\_\'', '\Avastin\_(Bevacizumab)\_\'', '\Cyramza\_(Ramucirumab)\_\'', '\Enhertu\_(Fam-Trastuzumab\_Deruxtecan-nxki)\_\'', '\Etopophos\_(Etoposide\_Phosphate)\_\'', '\Exkivity\_(Mobocertinib\_Succinate)\_\'', '\Gavreto\_(Pralsetinib)\_\'', '\Gemzar\_(Gemcitabine\_Hydrochloride)\_\'', '\Gilotrif\_(Afatinib\_Dimaleate)\_\'', '\Hycamtin\_(Topotecan\_Hydrochloride)\_\'', '\Imfinzi\_(Durvalumab)\_\'', '\Imjudo\_(Tremelimumab-actl)\_\'', '\Infugem\_(Gemcitabine\_Hydrochloride)\_\'', '\Iressa\_(Gefitinib)\_\'', '\Keytruda\_(Pembrolizumab)\_\'', '\Krazati\_(Adagrasib)\_\'', '\Libtayo\_(Cemiplimab-rwlc)\_\'', '\Lorbrena\_(Lorlatinib)\_\'', '\Lumakras\_(Sotorasib)\_\'', '\Mekinist\_(Trametinib\_Dimethyl\_Sulfoxide)\_\'', '\Mvasi\_(Bevacizumab)\_\'', '\Opdivo\_(Nivolumab)\_\'', '\Portrazza\_(Necitumumab)\_\'', '\Retevmo\_(Selpercatinib)\_\'', '\Rozlytrek\_(Entrectinib)\_\'', '\Rybrevant\_(Amivantamab-vmjw)\_\'', '\Tabrecta\_(Capmatinib\_Hydrochloride)\_\'', '\Tafinlar\_(Dabrafenib\_Mesylate)\_\'', '\Tagrisso\_(Osimertinib\_Mesylate)\_\'', '\Taxotere\_(Docetaxel)\_\'', '\Tecentriq\_(Atezolizumab)\_\'', '\Tepmetko\_(Tepotinib\_Hydrochloride)\_\'', '\Trexall\_(Methotrexate\_Sodium)\_\'', '\Vizimpro\_(Dacomitinib)\_\'', '\Xalkori\_(Crizotinib)\_\'', '\Yervoy\_(Ipilimumab)\_\'', '\Zirabev\_(Bevacizumab)\_\'', '\Zykadia\_(Ceritinib)\_\'', **4A\_NSCLC**, 4B\_NSCLC, Adagrasib\_, Adherence\_Based\_on\_Socioeconomics\_LC, Adherence\_Factors\_LC, Adverse\_Reactions\_ABRAX, Adverse\_Reactions\_ADAGR, Adverse\_Reactions\_AFATI, Adverse\_Reactions\_AFINI, Adverse\_Reactions\_AFINIT, Adverse\_Reactions\_ALECE, Adverse\_Reactions\_ALIMT, Adverse\_Reactions\_ALUNB, Adverse\_Reactions\_ARYMS, Adverse\_Reactions\_AMIVA, Adverse\_Reactions\_ATEZO, Adverse\_Reactions\_AVAST, Adverse\_Reactions\_BRIGA, Adverse\_Reactions\_CAPMA, Adverse\_Reactions\_CEMIP, Adverse\_Reactions\_CYRAM, Adverse\_Reactions\_DOXOR, Adverse\_Reactions\_DURVA, Adverse\_Reactions\_ENHER, Adverse\_Reactions\_ENTRE, Adverse\_Reactions\_ERLOT, Adverse\_Reactions\_ETOP, Adverse\_Reactions\_ETOPO, Adverse\_Reactions\_EXKIV, Adverse\_Reactions\_GAVRE, Adverse\_Reactions\_GEFIT, Adverse\_Reactions\_GEMZA, Adverse\_Reactions\_GILOT, Adverse\_Reactions\_HYCAM, Adverse\_Reactions\_IMFIN, Adverse\_Reactions\_IMJUD, Adverse\_Reactions\_INFUG, Adverse\_Reactions\_IRESS, Adverse\_Reactions\_KEYTR, Adverse\_Reactions\_KRAZA, Adverse\_Reactions\_LIBTA, Adverse\_Reactions\_LORBR, Adverse\_Reactions\_LUMAK, Adverse\_Reactions\_LURB, Adverse\_Reactions\_MEKIN, Adverse\_Reactions\_METH, Adverse\_Reactions\_MVASI, Adverse\_Reactions\_OPDIV, Adverse\_Reactions\_PORTR, Adverse\_Reactions\_RAMUC, Adverse\_Reactions\_RETEV, Adverse\_Reactions\_ROZLY, Adverse\_Reactions\_RYBRE, Adverse\_Reactions\_SELPE, Adverse\_Reactions\_SOTOR, Adverse\_Reactions\_TABRE, Adverse\_Reactions\_TAFIN, Adverse\_Reactions\_TAGRIS, Adverse\_Reactions\_TAXOT, Adverse\_Reactions\_TECEN, Adverse\_Reactions\_TEPME, Adverse\_Reactions\_TOPO, Adverse\_Reactions\_TRAME, Adverse\_Reactions\_TREME, Adverse\_Reactions\_TREXA, Adverse\_Reactions\_VINOR, Adverse\_Reactions\_VIZIM, Adverse\_Reactions\_XALKO, Adverse\_Reactions\_YERVO, Adverse\_Reactions\_ZIRAB, Adverse\_Reactions\_ZYKAD, Afatinib\_Dimaleate\_, Age, Air\_Pollution, Amivantamab-vmjw\_, Atezolizumab\_, Behavioral\_Factors\_LC, Beta\_Carotene\_Supplements\_LC, Bio\_Sensors\_LC, Biological\_Effects\_LC, Breathalyzer\_LC, Breathing\_LC, Brigatinib\_, Capmatinib\_Hydrochloride\_, Causes\_and\_Risks\_LC, Cemiplimab-rwlc\_, Chemical\_Sensors\_LC, Choosing\_Quality\_of\_Life\_-\_Reasons\_People\_Forego\_Treatment, Choosing\_Survival\_-\_Deciding\_to\_Undergo\_Treatment, Complications\_LC, Contraindications\_ABRAX, Contraindications\_ADAGR, Contraindications\_AFATI, Contraindications\_AFINI, Contraindications\_AFINIT, Contraindications\_ALECE, Contraindications\_ALIMT, Contraindications\_ALUNB, Contraindications\_ARYMS, Contraindications\_AMIVA, Contraindications\_ATEZO, Contraindications\_AVAST, Contraindications\_BRIGA, Contraindications\_CAPMA, Contraindications\_CEMIP, Contraindications\_CYRAM, Contraindications\_DOXOR, Contraindications\_DURVA,

Contraindications\_ENHER, Contraindications\_ENTRE, Contraindications\_ERLOT, Contraindications\_ETOP, Contraindications\_ETOPO, Contraindications\_EXKIV, Contraindications\_GAVRE, Contraindications\_GEFIT, Contraindications\_GEMZA, Contraindications\_GILOT, Contraindications\_HYCAM, Contraindications\_IMFIN, Contraindications\_IMJUD, Contraindications\_INFUG, Contraindications\_IRESS, Contraindications\_KEYTR, Contraindications\_KRAZA, Contraindications\_LIBTA, Contraindications\_LORBR, Contraindications\_LUMAK, Contraindications\_LURB, Contraindications\_MEKIN, Contraindications\_METH, Contraindications\_MVASI, Contraindications\_OPDIV, Contraindications\_PORTR, Contraindications\_RAMUC, Contraindications\_RETEV, Contraindications\_ROZLY, Contraindications\_RYBRE, Contraindications\_SELPE, Contraindications\_SOTOR, Contraindications\_TABRE, Contraindications\_TAFIN, Contraindications\_TAGRIS, Contraindications\_TAXOT, Contraindications\_TECEN, Contraindications\_TEPME, Contraindications\_TOPO, Contraindications\_TRAME, Contraindications\_TREME, Contraindications\_TREXA, Contraindications\_VINOR, Contraindications\_VIZIM, Contraindications\_XALKO, Contraindications\_YERVO, Contraindications\_ZIRAB, Contraindications\_ZYKAD, Cultural\_Beliefs\_and\_Perceptions, Cultural\_LC, Degrees\_of\_Smoking\_LC, Demographic\_Factors\_LC, Diet\_LC, Disparities\_in\_Incidence, Dosage\_and\_Administration\_ABRAX, Dosage\_and\_Administration\_ADAGR, Dosage\_and\_Administration\_AFATI, Dosage\_and\_Administration\_AFINI, Dosage\_and\_Administration\_AFINIT, Dosage\_and\_Administration\_ALECE, Dosage\_and\_Administration\_ALIMT, Dosage\_and\_Administration\_ALUNB, Dosage\_and\_Administration\_ARYMS, Dosage\_and\_Administration\_AMIVA, Dosage\_and\_Administration\_ATEZO, Dosage\_and\_Administration\_AVAST, Dosage\_and\_Administration\_BRIGA, Dosage\_and\_Administration\_CAPMA, Dosage\_and\_Administration\_CEMIP, Dosage\_and\_Administration\_CYRAM, Dosage\_and\_Administration\_DOXOR, Dosage\_and\_Administration\_DURVA, Dosage\_and\_Administration\_ENHER, Dosage\_and\_Administration\_ENTRE, Dosage\_and\_Administration\_ERLOT, Dosage\_and\_Administration\_ETOP, Dosage\_and\_Administration\_ETOPO, Dosage\_and\_Administration\_EXKIV, Dosage\_and\_Administration\_GAVRE, Dosage\_and\_Administration\_GEFIT, Dosage\_and\_Administration\_GEMZA, Dosage\_and\_Administration\_GILOT, Dosage\_and\_Administration\_HYCAM, Dosage\_and\_Administration\_IMFIN, Dosage\_and\_Administration\_IMJUD, Dosage\_and\_Administration\_INFUG, Dosage\_and\_Administration\_IRESS, Dosage\_and\_Administration\_KEYTR, Dosage\_and\_Administration\_KRAZA, Dosage\_and\_Administration\_LIBTA, Dosage\_and\_Administration\_LORBR, Dosage\_and\_Administration\_LUMAK, Dosage\_and\_Administration\_LURB, Dosage\_and\_Administration\_MEKIN, Dosage\_and\_Administration\_METH, Dosage\_and\_Administration\_MVASI, Dosage\_and\_Administration\_OPDIV, Dosage\_and\_Administration\_PORTR, Dosage\_and\_Administration\_RAMUC, Dosage\_and\_Administration\_RETEV, Dosage\_and\_Administration\_ROZLY, Dosage\_and\_Administration\_RYBRE, Dosage\_and\_Administration\_SELPE, Dosage\_and\_Administration\_SOTOR, Dosage\_and\_Administration\_TABRE, Dosage\_and\_Administration\_TAFIN, Dosage\_and\_Administration\_TAGRIS, Dosage\_and\_Administration\_TAXOT, Dosage\_and\_Administration\_TECEN, Dosage\_and\_Administration\_TEPME, Dosage\_and\_Administration\_TOPO, Dosage\_and\_Administration\_TRAME, Dosage\_and\_Administration\_TREME, Dosage\_and\_Administration\_TREXA, Dosage\_and\_Administration\_VINOR, Dosage\_and\_Administration\_VIZIM, Dosage\_and\_Administration\_XALKO, Dosage\_and\_Administration\_YERVO, Dosage\_and\_Administration\_ZIRAB, Dosage\_and\_Administration\_ZYKAD, Dosage\_Forms\_and\_Strengths\_ABRAX, Dosage\_Forms\_and\_Strengths\_ADAGR, Dosage\_Forms\_and\_Strengths\_AFATI, Dosage\_Forms\_and\_Strengths\_AFINI, Dosage\_Forms\_and\_Strengths\_AFINIT, Dosage\_Forms\_and\_Strengths\_ALECE, Dosage\_Forms\_and\_Strengths\_ALIMT, Dosage\_Forms\_and\_Strengths\_ALUNB, Dosage\_Forms\_and\_Strengths\_ARYMS, Dosage\_Forms\_and\_Strengths\_AMIVA, Dosage\_Forms\_and\_Strengths\_ATEZO, Dosage\_Forms\_and\_Strengths\_AVAST, Dosage\_Forms\_and\_Strengths\_BRIGA, Dosage\_Forms\_and\_Strengths\_CAPMA, Dosage\_Forms\_and\_Strengths\_CEMIP, Dosage\_Forms\_and\_Strengths\_CYRAM, Dosage\_Forms\_and\_Strengths\_DOXOR, Dosage\_Forms\_and\_Strengths\_DURVA, Dosage\_Forms\_and\_Strengths\_ENHER, Dosage\_Forms\_and\_Strengths\_ENTRE, Dosage\_Forms\_and\_Strengths\_ERLOT, Dosage\_Forms\_and\_Strengths\_ETOP, Dosage\_Forms\_and\_Strengths\_ETOPO, Dosage\_Forms\_and\_Strengths\_EXKIV, Dosage\_Forms\_and\_Strengths\_GAVRE, Dosage\_Forms\_and\_Strengths\_GEFIT, Dosage\_Forms\_and\_Strengths\_GEMZA, Dosage\_Forms\_and\_Strengths\_GILOT, Dosage\_Forms\_and\_Strengths\_HYCAM, Dosage\_Forms\_and\_Strengths\_IMFIN, Dosage\_Forms\_and\_Strengths\_IMJUD, Dosage\_Forms\_and\_Strengths\_INFUG, Dosage\_Forms\_and\_Strengths\_IRESS, Dosage\_Forms\_and\_Strengths\_KEYTR, Dosage\_Forms\_and\_Strengths\_KRAZA, Dosage\_Forms\_and\_Strengths\_LIBTA, Dosage\_Forms\_and\_Strengths\_LORBR, Dosage\_Forms\_and\_Strengths\_LUMAK, Dosage\_Forms\_and\_Strengths\_LURB, Dosage\_Forms\_and\_Strengths\_MEKIN, Dosage\_Forms\_and\_Strengths\_METH, Dosage\_Forms\_and\_Strengths\_MVASI, Dosage\_Forms\_and\_Strengths\_OPDIV, Dosage\_Forms\_and\_Strengths\_PORTR, Dosage\_Forms\_and\_Strengths\_RAMUC, Dosage\_Forms\_and\_Strengths\_RETEV, Dosage\_Forms\_and\_Strengths\_ROZLY, Dosage\_Forms\_and\_Strengths\_RYBRE, Dosage\_Forms\_and\_Strengths\_SELPE, Dosage\_Forms\_and\_Strengths\_SOTOR, Dosage\_Forms\_and\_Strengths\_TABRE, Dosage\_Forms\_and\_Strengths\_TAFIN, Dosage\_Forms\_and\_Strengths\_TAGRIS, Dosage\_Forms\_and\_Strengths\_TAXOT, Dosage\_Forms\_and\_Strengths\_TECEN, Dosage\_Forms\_and\_Strengths\_TEPME, Dosage\_Forms\_and\_Strengths\_TOPO, Dosage\_Forms\_and\_Strengths\_TRAME, Dosage\_Forms\_and\_Strengths\_TREME,

Dosage\_Forms\_and\_Strengths\_TREXA, Dosage\_Forms\_and\_Strengths\_VINOR,  
 Dosage\_Forms\_and\_Strengths\_VIZIM, Dosage\_Forms\_and\_Strengths\_XALKO,  
 Dosage\_Forms\_and\_Strengths\_YERVO, Dosage\_Forms\_and\_Strengths\_ZIRAB,  
 Dosage\_Forms\_and\_Strengths\_ZYKAD, Doxorubicin\_Hydrochloride\_, Drug\_Interactions\_ABRAX,  
 Drug\_Interactions\_ADAGR, Drug\_Interactions\_AFATI, Drug\_Interactions\_AFINI, Drug\_Interactions\_AFINIT,  
 Drug\_Interactions\_ALECE, Drug\_Interactions\_ALIMT, Drug\_Interactions\_ALUNB, Drug\_Interactions\_ALYMS,  
 Drug\_Interactions\_AMIVA, Drug\_Interactions\_ATEZO, Drug\_Interactions\_AVAST, Drug\_Interactions\_BRIGA,  
 Drug\_Interactions\_CAPMA, Drug\_Interactions\_CEMIP, Drug\_Interactions\_CYRAM, Drug\_Interactions\_DOXOR,  
 Drug\_Interactions\_DURVA, Drug\_Interactions\_ENHER, Drug\_Interactions\_ENTRE, Drug\_Interactions\_ERLOT,  
 Drug\_Interactions\_ETOP, Drug\_Interactions\_ETOPO, Drug\_Interactions\_EXKIV, Drug\_Interactions\_GAVRE,  
 Drug\_Interactions\_GEFIT, Drug\_Interactions\_GEMZA, Drug\_Interactions\_GILOT, Drug\_Interactions\_HYCAM,  
 Drug\_Interactions\_IMFIN, Drug\_Interactions\_IMJUD, Drug\_Interactions\_INFUG, Drug\_Interactions\_IRESS,  
 Drug\_Interactions\_KEYTR, Drug\_Interactions\_KRAZA, Drug\_Interactions\_LIBTA, Drug\_Interactions\_LORBR,  
 Drug\_Interactions\_LUMAK, Drug\_Interactions\_LURB, Drug\_Interactions\_MEKIN, Drug\_Interactions\_METH,  
 Drug\_Interactions\_MVASI, Drug\_Interactions\_OPDIV, Drug\_Interactions\_PORTR, Drug\_Interactions\_RAMUC,  
 Drug\_Interactions\_RETEV, Drug\_Interactions\_ROZLY, Drug\_Interactions\_RYBRE, Drug\_Interactions\_SELPE,  
 Drug\_Interactions\_SOTOR, Drug\_Interactions\_TABRE, Drug\_Interactions\_TAFIN, Drug\_Interactions\_TAGRIS,  
 Drug\_Interactions\_TAXOT, Drug\_Interactions\_TECEN, Drug\_Interactions\_TEPME, Drug\_Interactions\_TOPO,  
 Drug\_Interactions\_TRAME, Drug\_Interactions\_TREME, Drug\_Interactions\_TREXA, Drug\_Interactions\_VINOR,  
 Drug\_Interactions\_VIZIM, Drug\_Interactions\_XALKO, Drug\_Interactions\_YERVO, Drug\_Interactions\_ZIRAB,  
 Drug\_Interactions\_ZYKAD, Durvalumab\_, E-Cigarettes\_LC, Electronic\_Sensors\_LC, Emotions\_LC,  
 End\_of\_Life\_Decisions, Entrectinib\_, Environmental\_Factors\_LC, Enzymatic\_Sensors\_LC,  
 Erlotinib\_Hydrochloride\_, Etoposide\_, Exercise\_LC, Extensive\_Stage\_SCLC, Family\_History\_LC, Gefitinib\_,  
 Genomic\_Sequencing\_LC, Geographical\_Location, Habits\_LC, HIV\_Infection\_LC, Immunosensors\_LC,  
 Increased\_Susceptibility\_LC, Indications\_and\_Usage\_ABRAX, Indications\_and\_Usage\_ADAGR,  
 Indications\_and\_Usage\_AFATI, Indications\_and\_Usage\_AFINI, Indications\_and\_Usage\_AFINIT,  
 Indications\_and\_Usage\_ALECE, Indications\_and\_Usage\_ALIMT, Indications\_and\_Usage\_ALUNB,  
 Indications\_and\_Usage\_ALYMS, Indications\_and\_Usage\_AMIVA, Indications\_and\_Usage\_ATEZO,  
 Indications\_and\_Usage\_AVAST, Indications\_and\_Usage\_BRIGA, Indications\_and\_Usage\_CAPMA,  
 Indications\_and\_Usage\_CEMIP, Indications\_and\_Usage\_CYRAM, Indications\_and\_Usage\_DOXOR,  
 Indications\_and\_Usage\_DURVA, Indications\_and\_Usage\_ENHER, Indications\_and\_Usage\_ENTRE,  
 Indications\_and\_Usage\_ERLOT, Indications\_and\_Usage\_ETOP, Indications\_and\_Usage\_ETOPO,  
 Indications\_and\_Usage\_EXKIV, Indications\_and\_Usage\_GAVRE, Indications\_and\_Usage\_GEFIT,  
 Indications\_and\_Usage\_GEMZA, Indications\_and\_Usage\_GILOT, Indications\_and\_Usage\_HYCAM,  
 Indications\_and\_Usage\_IMFIN, Indications\_and\_Usage\_IMJUD, Indications\_and\_Usage\_INFUG,  
 Indications\_and\_Usage\_IRESS, Indications\_and\_Usage\_KEYTR, Indications\_and\_Usage\_KRAZA,  
 Indications\_and\_Usage\_LIBTA, Indications\_and\_Usage\_LORBR, Indications\_and\_Usage\_LUMAK,  
 Indications\_and\_Usage\_LURB, Indications\_and\_Usage\_MEKIN, Indications\_and\_Usage\_METH,  
 Indications\_and\_Usage\_MVASI, Indications\_and\_Usage\_OPDIV, Indications\_and\_Usage\_PORTR,  
 Indications\_and\_Usage\_RAMUC, Indications\_and\_Usage\_RETEV, Indications\_and\_Usage\_ROZLY,  
 Indications\_and\_Usage\_RYBRE, Indications\_and\_Usage\_SELPE, Indications\_and\_Usage\_SOTOR,  
 Indications\_and\_Usage\_TABRE, Indications\_and\_Usage\_TAFIN, Indications\_and\_Usage\_TAGRIS,  
 Indications\_and\_Usage\_TAXOT, Indications\_and\_Usage\_TECEN, Indications\_and\_Usage\_TEPME,  
 Indications\_and\_Usage\_TOPO, Indications\_and\_Usage\_TRAME, Indications\_and\_Usage\_TREME,  
 Indications\_and\_Usage\_TREXA, Indications\_and\_Usage\_VINOR, Indications\_and\_Usage\_VIZIM,  
 Indications\_and\_Usage\_XALKO, Indications\_and\_Usage\_YERVO, Indications\_and\_Usage\_ZIRAB,  
 Indications\_and\_Usage\_ZYKAD, Limited\_Stage\_SCLC, Living\_with\_LC\_LC, Location\_LC, Lurbinectedin\_,  
 Marijuana\_Smoking\_LC, Medications\_LC, Methotrexate\_Sodium\_, Never-Smokers\_LC, Non-  
 Small\_Cell\_LC\_NSCLC, Non-Small\_Cell\_Lung\_Cancer, Non-Small\_Cell\_Medication\_LC\_, Non-Smokers\_LC, Non-  
 Smokers\_NSCLC, Non-Smokers\_SCLC, Nutrition\_LC, Occupational\_Exposure,  
 Physical\_Activity\_For\_Mitigation\_of\_LC, Physical\_Activity\_For\_Prevention\_Of\_LC, Preventative\_habits\_LC,  
 Quitting/Not\_Smoking\_LC, Racial/Ethnic, Radiation\_Exposure\_LC, Ramucirumab\_, Recurring\_LC\_NSCLC,  
 Recurring\_LC\_SCLC, Rural\_LC, Second-hand\_Smoke\_LC, Secondhand\_Smoke\_LC, Selpercatinib\_,  
 Sensor\_Factors\_LC, Size\_of\_the\_community\_LC, Sleep\_LC, Small\_Cell\_LC, Small\_Cell\_LC\_SCLC,  
 Small\_Cell\_Lung\_Cancer, Small\_Cell\_Medication\_LC\_, Smoke\_LC, Smokers\_LC, Smokers\_NSCLC,  
 Smokers\_SCLC, Smoking\_LC, Smoking\_Marijuana\_LC, Smoking\_Other\_Drugs\_LC, Smoking\_Tobacco\_LC,  
 Socioeconomics\_LC, Sotorasib\_, Stage\_0\_NSCLC, Stage\_1\_NSCLC, Stage\_1\_SCLC, Stage\_2\_NSCLC,  
 Stage\_3A\_NSCLC, Stage\_3B\_NSCLC, Support\_Groups\_LC, Symptoms\_and\_Tests\_LC, Symptoms\_NSC,  
 Symptoms\_SC, Tests\_NSC, Tests\_SC, Tobacco\_Smoking, Tobacco\_Smoking\_LC, Topotecan\_Hydrochloride\_,  
 Tramentinib\_Dimethyl\_Sulfoxide, Treatment\_Regimens\_LC, Tremelimumab-actl\_, Urban\_LC,  
 Use\_in\_Specific\_Populations\_ABRAX, Use\_in\_Specific\_Populations\_ADAGR, Use\_in\_Specific\_Populations\_AFATI,  
 Use\_in\_Specific\_Populations\_AFINI, Use\_in\_Specific\_Populations\_AFINIT, Use\_in\_Specific\_Populations\_ALECE,  
 Use\_in\_Specific\_Populations\_ALIMT, Use\_in\_Specific\_Populations\_ALUNB, Use\_in\_Specific\_Populations\_ALYMS,  
 Use\_in\_Specific\_Populations\_AMIVA, Use\_in\_Specific\_Populations\_ATEZO, Use\_in\_Specific\_Populations\_AVAST,  
 Use\_in\_Specific\_Populations\_BRIGA, Use\_in\_Specific\_Populations\_CAPMA, Use\_in\_Specific\_Populations\_CEMIP,

Use\_in\_Specific\_Populations\_CYRAM, Use\_in\_Specific\_Populations\_DOXOR,  
Use\_in\_Specific\_Populations\_DURVA, Use\_in\_Specific\_Populations\_ENHER,  
Use\_in\_Specific\_Populations\_ENTRE, Use\_in\_Specific\_Populations\_ERLOT, Use\_in\_Specific\_Populations\_ETOP,  
Use\_in\_Specific\_Populations\_ETOPO, Use\_in\_Specific\_Populations\_EXKIV, Use\_in\_Specific\_Populations\_GAVRE,  
Use\_in\_Specific\_Populations\_GEFIT, Use\_in\_Specific\_Populations\_GEMZA, Use\_in\_Specific\_Populations\_GILOT,  
Use\_in\_Specific\_Populations\_HYCAM, Use\_in\_Specific\_Populations\_IMFIN, Use\_in\_Specific\_Populations\_IMJUD,  
Use\_in\_Specific\_Populations\_INFUG, Use\_in\_Specific\_Populations\_IRESS, Use\_in\_Specific\_Populations\_KEYTR,  
Use\_in\_Specific\_Populations\_KRAZA, Use\_in\_Specific\_Populations\_LIBTA, Use\_in\_Specific\_Populations\_LORBR,  
Use\_in\_Specific\_Populations\_LUMAK, Use\_in\_Specific\_Populations\_LURB, Use\_in\_Specific\_Populations\_MEKIN,  
Use\_in\_Specific\_Populations\_METH, Use\_in\_Specific\_Populations\_MVASI, Use\_in\_Specific\_Populations\_OPDIV,  
Use\_in\_Specific\_Populations\_PORTR, Use\_in\_Specific\_Populations\_RAMUC, Use\_in\_Specific\_Populations\_RETEV,  
Use\_in\_Specific\_Populations\_ROZLY, Use\_in\_Specific\_Populations\_RYBRE, Use\_in\_Specific\_Populations\_SELPE,  
Use\_in\_Specific\_Populations\_SOTOR, Use\_in\_Specific\_Populations\_TABRE, Use\_in\_Specific\_Populations\_TAFIN,  
Use\_in\_Specific\_Populations\_TAGRIS, Use\_in\_Specific\_Populations\_TAXOT,  
Use\_in\_Specific\_Populations\_TECEN, Use\_in\_Specific\_Populations\_TEPME, Use\_in\_Specific\_Populations\_TOPO,  
Use\_in\_Specific\_Populations\_TRAME, Use\_in\_Specific\_Populations\_TREME, Use\_in\_Specific\_Populations\_TREXA,  
Use\_in\_Specific\_Populations\_VINOR, Use\_in\_Specific\_Populations\_VIZIM, Use\_in\_Specific\_Populations\_XALKO,  
Use\_in\_Specific\_Populations\_YERVO, Use\_in\_Specific\_Populations\_ZIRAB, Use\_in\_Specific\_Populations\_ZYKAD,  
Vinorelbine\_Tartrate\_, Warnings\_and\_Precautions\_ABRAX, Warnings\_and\_Precautions\_ADAGR,  
Warnings\_and\_Precautions\_AFATI, Warnings\_and\_Precautions\_AFINI, Warnings\_and\_Precautions\_AFINIT,  
Warnings\_and\_Precautions\_ALECE, Warnings\_and\_Precautions\_ALIMT, Warnings\_and\_Precautions\_ALUNB,  
Warnings\_and\_Precautions\_ALYMS, Warnings\_and\_Precautions\_AMIVA, Warnings\_and\_Precautions\_ATEZO,  
Warnings\_and\_Precautions\_AVAST, Warnings\_and\_Precautions\_BRIGA, Warnings\_and\_Precautions\_CAPMA,  
Warnings\_and\_Precautions\_CEMIP, Warnings\_and\_Precautions\_CYRAM, Warnings\_and\_Precautions\_DOXOR,  
Warnings\_and\_Precautions\_DURVA, Warnings\_and\_Precautions\_ENHER, Warnings\_and\_Precautions\_ENTRE,  
Warnings\_and\_Precautions\_ERLOT, Warnings\_and\_Precautions\_ETOP, Warnings\_and\_Precautions\_ETOPO,  
Warnings\_and\_Precautions\_EXKIV, Warnings\_and\_Precautions\_GAVRE, Warnings\_and\_Precautions\_GEFIT,  
Warnings\_and\_Precautions\_GEMZA, Warnings\_and\_Precautions\_GILOT, Warnings\_and\_Precautions\_HYCAM,  
Warnings\_and\_Precautions\_IMFIN, Warnings\_and\_Precautions\_IMJUD, Warnings\_and\_Precautions\_INFUG,  
Warnings\_and\_Precautions\_IRESS, Warnings\_and\_Precautions\_KEYTR, Warnings\_and\_Precautions\_KRAZA,  
Warnings\_and\_Precautions\_LIBTA, Warnings\_and\_Precautions\_LORBR, Warnings\_and\_Precautions\_LUMAK,  
Warnings\_and\_Precautions\_LURB, Warnings\_and\_Precautions\_MEKIN, Warnings\_and\_Precautions\_METH,  
Warnings\_and\_Precautions\_MVASI, Warnings\_and\_Precautions\_OPDIV, Warnings\_and\_Precautions\_PORTR,  
Warnings\_and\_Precautions\_RAMUC, Warnings\_and\_Precautions\_RETEV, Warnings\_and\_Precautions\_ROZLY,  
Warnings\_and\_Precautions\_RYBRE, Warnings\_and\_Precautions\_SELPE, Warnings\_and\_Precautions\_SOTOR,  
Warnings\_and\_Precautions\_TABRE, Warnings\_and\_Precautions\_TAFIN, Warnings\_and\_Precautions\_TAGRIS,  
Warnings\_and\_Precautions\_TAXOT, Warnings\_and\_Precautions\_TECEN, Warnings\_and\_Precautions\_TEPME,  
Warnings\_and\_Precautions\_TOPO, Warnings\_and\_Precautions\_TRAME, Warnings\_and\_Precautions\_TREME,  
Warnings\_and\_Precautions\_TREXA, Warnings\_and\_Precautions\_VINOR, Warnings\_and\_Precautions\_VIZIM,  
Warnings\_and\_Precautions\_XALKO, Warnings\_and\_Precautions\_YERVO, Warnings\_and\_Precautions\_ZIRAB,  
Warnings\_and\_Precautions\_ZYKAD

OWL HTML inside